Mo Makoto, Fukuda Ikuo, Nakamura Mashio, Yamada Norikazu, Takayama Morimasa, Maeda Hideaki, Yamashita Takeshi, Ikeda Takanori, Yamazaki Tsutomu, Okumura Yasuo, Hirayama Atsushi
Department of Cardiovascular Surgery, 73663Yokohama Minami Kyosai Hospital, Yokohama, Japan.
Department of Cardiology, Keimeikai Yokawa Hospital, Miki, Japan.
Phlebology. 2023 Feb;38(1):4-15. doi: 10.1177/02683555221141310. Epub 2022 Nov 26.
We assessed the effectiveness and safety of rivaroxaban in patients with isolated distal deep vein thrombosis (IDDVT).
Symptomatic venous thromboembolism (VTE) and major bleeding were assessed.
Of 1016 patients with acute symptomatic/asymptomatic DVT and/or pulmonary embolism treated with rivaroxaban, 288 had IDDVT and 294 had proximal DVT (pDVT). The IDDVT group had fewer patients on the higher rivaroxaban dose (30 mg/day) (42.7% vs. 66.0%) and a shorter treatment duration (135.5 vs 369.5 days) than the pDVT group. VTE recurrence occurred in 14 and 11 patients with IDDVT and pDVT, respectively (2.89% vs. 2.29% per patient-year; = 0.534). Major bleeding was less frequent in the IDDVT group (1.55% vs. 4.53% per patient-year; = 0.044). Comparable effectiveness and safety were observed with 15 and 30 mg/day rivaroxaban in the IDDVT group.
Short-term, low-dose rivaroxaban seems safe and effective for IDDVT treatment.
我们评估了利伐沙班在孤立性远端深静脉血栓形成（IDDVT）患者中的有效性和安全性。
对有症状的静脉血栓栓塞症（VTE）和大出血情况进行了评估。
在1016例接受利伐沙班治疗的急性有症状/无症状深静脉血栓形成（DVT）和/或肺栓塞患者中，288例患有IDDVT，294例患有近端深静脉血栓形成（pDVT）。与pDVT组相比，IDDVT组接受较高利伐沙班剂量（30毫克/天）的患者较少（42.7%对66.0%），治疗持续时间较短（135.5天对369.5天）。IDDVT组和pDVT组分别有14例和11例患者出现VTE复发（每年每例患者分别为2.89%对2.29%；P = 0.534）。IDDVT组大出血的发生率较低（每年每例患者分别为1.55%对4.53%；P = 0.044）。在IDDVT组中，15毫克/天和30毫克/天的利伐沙班观察到了相当的有效性和安全性。
短期、低剂量利伐沙班治疗IDDVT似乎安全有效。
